Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 2/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16744186 | 1.00 | FFAR4 (0.52) | FFAR4FFAR1NFKB1GPR84CA1 | |
| SCHEMBL28277114 | 0.98 | FFAR1 (0.55) | FFAR4FFAR1NFKB1GPR84CA1 | |
| SCHEMBL8897084 | 0.98 | FFAR1 (0.55) | FFAR4FFAR1NFKB1GPR84CA1 | |
| SCHEMBL8388624 | 0.98 | FFAR1 (0.55) | FFAR4FFAR1NFKB1GPR84CA1 | |
| SCHEMBL17526843 | 0.92 | FFAR4 (0.54) | FFAR4FFAR1NFKB1GPR84CA1 | |
| SCHEMBL107867 | 0.92 | FFAR4 (0.43) | FFAR4FFAR1NFKB1GPR84CA1 | |
| SCHEMBL17526740 | 0.92 | FFAR4 (0.54) | FFAR4FFAR1NFKB1GPR84CA1 | |
| SCHEMBL16114411 | 0.90 | FFAR1 (0.57) | FFAR4FFAR1NFKB1GPR84CA1 | |
| SCHEMBL6759532 | 0.90 | FFAR1 (0.57) | FFAR4FFAR1NFKB1GPR84CA1 | |
| SCHEMBL11708323 | 0.90 | FFAR4 (0.52) | FFAR4FFAR1NFKB1GPR84CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000088-A1 | ANT CONTROL AGENT AND ANT CONTROL METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-01-02 | — | — | US | disclosed |
| EP-4424164-A1 | ANT CONTROL AGENT AND ANT CONTROL METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-09-04 | — | — | EP | disclosed |
| CN-118139527-A | Ant control agent and ant control method | 信越化学工业株式会社 | 2024-06-04 | — | — | CN | disclosed |
| US-11795135-B2 | Prostacyclin compounds, compositions and methods of use thereof | INSMED INCORPORATED (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795135-B2 | Prostacyclin compounds, compositions and methods of use thereof | INSMED INCORPORATED (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230250051-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | INSMED INCORPORATED (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230250051-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | INSMED INCORPORATED (US) | 2023-08-10 | — | — | US | disclosed |
| WO-2023074396-A1 | ANT CONTROL AGENT AND ANT CONTROL METHOD | 信越化学工業株式会社 | 2023-05-04 | — | — | WO | disclosed |
| US-11148997-B2 | Methods of manufacturing treprostinil and treprostinil derivative prodrugs | INSMED INCORPORATED (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210276940-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | BIOPHARMA CREDIT PLC (GB) | 2021-09-09 | — | — | US | disclosed |
| US-20170320813-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | BIOPHARMA CREDIT PLC (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170049739-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | INSMED INCORPORATED | 2017-02-23 | — | — | US | disclosed |
| US-20170049739-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | INSMED INCORPORATED | 2017-02-23 | — | — | US | disclosed |
| US-20160318844-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | INSMED INC (US) | 2016-11-03 | — | — | US | disclosed |
| US-9469600-B2 | Prostacyclin compounds, compositions and methods of use thereof | INSMED INCORPORATED (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160256425-A1 | Prostacyclin Compounds, Compositions and Methods of use Thereof | BIOPHARMA CREDIT PLC (GB) | 2016-09-08 | — | — | US | disclosed |
| US-9255064-B2 | Prostacyclin compounds, compositions and methods of use thereof | INSMED INCORPORATED (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150175529-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | BIOPHARMA CREDIT PLC (GB) | 2015-06-25 | — | — | US | disclosed |
| US-20150148414-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | BIOPHARMA CREDIT PLC (GB) | 2015-05-28 | — | — | US | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250051-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | PTGIS, THOP1, PTGIR | FFAR4 1625/4885FFAR1 984/4885NFKB1 1719/4885 |
| US-20210276940-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | PTGIS, PTGIR, PTGER1 | FFAR4 1397/4885FFAR1 707/4885NFKB1 1422/4885 |
| US-20170049739-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | PTGIS, PTGIR, PTGER1 | FFAR4 1397/4885FFAR1 707/4885NFKB1 1422/4885 |
| US-11148997-B2 | Methods of manufacturing treprostinil and treprostinil derivative prodrugs | PTGIS, PTGER1, PTGIR | FFAR4 2099/4885FFAR1 984/4885NFKB1 1669/4885 |
| US-20160318844-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | PTGIS, PTGER1, PTGER3 | FFAR4 1278/4885FFAR1 435/4885NFKB1 2623/4885 |
| US-20150148414-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | PTGIS, PTGIR, PTGER1 | FFAR4 1397/4885FFAR1 707/4885NFKB1 1422/4885 |
| US-20170320813-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | PTGIS, THOP1, PTGIR | FFAR4 1691/4885FFAR1 1017/4885NFKB1 1646/4885 |
| US-11795135-B2 | Prostacyclin compounds, compositions and methods of use thereof | PTGIS, PTGIR, PTGER1 | FFAR4 1397/4885FFAR1 707/4885NFKB1 1422/4885 |
| US-20160256425-A1 | Prostacyclin Compounds, Compositions and Methods of use Thereof | PTGIS, PTGIR, PTGER1 | FFAR4 1397/4885FFAR1 707/4885NFKB1 1422/4885 |
| US-20150175529-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | PTGIS, PTGIR, PTGER1 | FFAR4 1397/4885FFAR1 707/4885NFKB1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.